Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of semaglutide injection versus Wegovy in Chinese adults with obesity
CTR20243356Phase 3Completed
- Sponsor
- Livzon Group Xinbeijiang Pharmaceutical
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Livzon Group Xinbeijiang Pharmaceutical. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20243356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243356.